[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Kosugi SI, Kanda T, Nishimaki T, Nakagawa S, Yajima K, Ohashi M, Hatakeyama K: Successful treatment for esophageal carcinoma with lung metastasis by induction chemotherapy followed by salvage esophagectomy: report of a case. World J Gastroenterol; 2006 Jul 7;12(25):4101-3
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment for esophageal carcinoma with lung metastasis by induction chemotherapy followed by salvage esophagectomy: report of a case.
  • We here report a case of a 51-year-old man with lung metastasis from esophageal carcinoma that was initially treated by combination chemotherapy consisting of fluorouracil and nedaplatin.
  • Because metastatic disease disappeared, salvage esophagectomy was performed.
  • Although chest wall recurrence developed at the thoracotomy wound, prolonged survival of 48 mo was achieved by local tumor resection and additional chemotherapy.
  • This combination chemotherapy is regarded as a promising and considerable treatment for metastatic esophageal carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / therapy. Esophagectomy. Lung Neoplasms / drug therapy. Salvage Therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Male. Middle Aged. Remission Induction / methods

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1993 Jan 21;53(2):220-3 [8425758.001]
  • [Cites] Cancer. 1995 Oct 1;76(7):1120-5 [8630886.001]
  • [Cites] Surg Today. 1997;27(4):330-3 [9086549.001]
  • [Cites] Hepatogastroenterology. 1998 Jan-Feb;45(19):201-5 [9496513.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2915-21 [10561371.001]
  • [Cites] Gan To Kagaku Ryoho. 1999 Dec;26(14):2233-6 [10635310.001]
  • [Cites] J Gastroenterol. 2001 Aug;36(8):560-3 [11519836.001]
  • [Cites] Int J Clin Oncol. 2002 Jun;7(3):192-6 [12109522.001]
  • [Cites] Scand J Gastroenterol. 2005 Aug;40(8):886-92 [16170897.001]
  • (PMID = 16810771.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4087733
  •  go-up   go-down


2. Li J, Ma S, Kang S, Xie J, Sheng X, Luo R: [Evaluation on survival in locally advanced non-small cell lung cancer (NSCLC) for multimodality treatment with or without operation]. Zhongguo Fei Ai Za Zhi; 2005 Dec 20;8(6):535-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation on survival in locally advanced non-small cell lung cancer (NSCLC) for multimodality treatment with or without operation].
  • BACKGROUND: It is uncertain that the effect of multimodality treatment with operation on survival for locally advanced non-small cell lung cancer (NSCLC).
  • The aim of this study is to evaluate the effect of multimodality treatment with or without operation on survival for locally advanced NSCLC.
  • Arm A (n=56): 39 cases were at stage IIIA, and 17 at stage IIIB; Median KPS was 80 (range from 70 to 90 ); Multimodality treatment program included operation, chemotherapy, radiotherapy and traditional Chinese herb medicine.
  • Preoperative or adjuvant chemotherapy regimens included MVP (mitomycin C, vindesine, cisplatin), NP (vinorelbine, cisplatin), TC (paclitaxel, carboplatin), GP (gemcitabine, cisplatin), which were repeated every 4 weeks for 4-6 cycles.
  • Arm B (n=58): 23 cases were at stage IIIA, and 35 at stage IIIB; Median KPS was 70 (range from 60 to 90); Treatment program was the same approximately as arm A except for no operation.
  • (1) Metastatic locations in follow-up, in turn, showed as: lymph node, pleural-lung, bone, brain, liver, pericardium, skin and adrenal;.
  • (1) Metastatic locations in follow-up, in turn, showed as: lymph node, pleural-lung, bone, brain, liver, pericardium, skin, adrenal, pancreatic and esophageal metastasis;.
  • CONCLUSIONS: Compared with non-operative multimodality treatment, operative multimodality treatment including lobectomy or pneumonectomy with mediastinal lymph node dissection can remarkably improve the survival in patients with locally advanced NSCLC.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21208544.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


3. Zhao JX, Li XF: [Effects of Fuzheng Yiliu Granule on expression of CD44v6 and nm23-H1 in esophageal carcinoma treated with radiotherapy]. Zhong Xi Yi Jie He Xue Bao; 2004 Jul;2(4):262-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of Fuzheng Yiliu Granule on expression of CD44v6 and nm23-H1 in esophageal carcinoma treated with radiotherapy].
  • OBJECTIVE: To evaluate the effects of Fuzheng Yiliu Granule on the expression of CD44v6 and nm23-H1 in esophageal carcinoma treated with radiotherapy.
  • METHODS: Sixty-three cases of esophageal carcinoma were randomly divided into two groups: Fuzheng Yiliu Granule plus radiotherapy treated group (n=30) and radiotherapy treated group (n=33).
  • The carcinoma specimens were obtained through endoscopic biopsy before and after twenty-one days of treatment.
  • The expression of CD44v6 and nm23-H1 was determined in the sixty-three specimens of esophageal carcinoma by immunohistochemical SABC methods.
  • RESULTS: After twenty-one days of treatment, the positive rates of CD44v6 in the Fuzheng Yiliu Granule plus radiotherapy treated group and the radiotherapy treated group were 40.0% and 69.7%, respectively, and there was significant difference between the two groups (P<0.05).
  • CONCLUSION: Fuzheng Yiliu Granule can lower the expression of CD44v6 in esophageal carcinoma, and may prevent infiltration and lymph node metastasis of esophageal carcinoma.
  • [MeSH-major] Antigens, CD44 / biosynthesis. Drugs, Chinese Herbal / therapeutic use. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Glycoproteins / biosynthesis. Nucleoside-Diphosphate Kinase / biosynthesis
  • [MeSH-minor] Aged. Esophagus / chemistry. Esophagus / drug effects. Esophagus / radiation effects. Humans. Immunohistochemistry. Medicine, Chinese Traditional. Middle Aged. NM23 Nucleoside Diphosphate Kinases. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15339409.001).
  • [ISSN] 1672-1977
  • [Journal-full-title] Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine
  • [ISO-abbreviation] Zhong Xi Yi Jie He Xue Bao
  • [Language] chi
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / CD44v6 antigen; 0 / Drugs, Chinese Herbal; 0 / Glycoproteins; 0 / NM23 Nucleoside Diphosphate Kinases; EC 2.7.4.6 / NME1 protein, human; EC 2.7.4.6 / Nucleoside-Diphosphate Kinase
  •  go-up   go-down


Advertisement
4. Ooki A, Yamashita K, Kikuchi S, Sakuramoto S, Katada N, Watanabe M: Phosphatase of regenerating liver-3 as a convergent therapeutic target for lymph node metastasis in esophageal squamous cell carcinoma. Int J Cancer; 2010 Aug 1;127(3):543-54
Hazardous Substances Data Bank. RHODANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphatase of regenerating liver-3 as a convergent therapeutic target for lymph node metastasis in esophageal squamous cell carcinoma.
  • Phosphatase of regenerating liver-3 (PRL-3) is a molecule associated with metastasis in a diverse of cancers, which, however, remains largely unknown in esophageal squamous cell carcinoma (ESCC).
  • We examined both the clinical significance of PRL-3 expression and its biological roles, and assessed possibilities as a therapeutic target in ESCC.
  • PRL-3 expression was found in 78% (69 of 88) of the primary ESCC on immunohistochemistry; it was the strong independent predictor for lymph node metastasis (LNM) on a multivariate logistic regression model (p = 0.0014, relative risk =15.20).
  • PRL-3 inhibitor (1-4-bromo-2-benzylidene rhodanine) also suppressed such metastatic properties in the cell lines with PRL-3 overexpression, but not with its low expression.
  • Collectively, PRL-3 overexpression is a frequent event associated with LNM and plays a causative role in promoting cancer progression.
  • Moreover, the expression status may be a landmark to select patients with benefit from PRL-3-targeted therapy.
  • Thus, PRL-3 could be a convergent therapeutic target against ESCC with LNM.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Enzyme Inhibitors / pharmacology. Esophageal Neoplasms / drug therapy. Lymphatic Metastasis / physiopathology. Neoplasm Proteins / antagonists & inhibitors. Protein Tyrosine Phosphatases / antagonists & inhibitors. Rhodanine / analogs & derivatives
  • [MeSH-minor] Apoptosis. Blotting, Western. Cell Cycle. Cell Line, Tumor. Cell Proliferation. Fluorescent Antibody Technique. Gene Expression Regulation, Enzymologic / drug effects. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Middle Aged. Multivariate Analysis. Polymerase Chain Reaction. RNA, Small Interfering

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • National BioResource Project. culture/stock collections - NBRP resources .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19960436.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 1-(2-bromobenzyloxy)-4-bromo-2-benzylidene rhodanine; 0 / Enzyme Inhibitors; 0 / Neoplasm Proteins; 0 / RNA, Small Interfering; 7O50LKL2G8 / Rhodanine; EC 3.1.3.48 / PTP4A3 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


5. Nagano H, Sakon M, Yasuda T, Dono K, Nakamori S, Yano M, Umeshita K, Shiozaki H, Okada A, Murakami T, Nakamura H, Monden M: [A case of postoperative multiple hepatic metastasis from esophageal cancer successfully treated by surgical resection and hepatic arterial infusion chemotherapy]. Gan To Kagaku Ryoho; 2001 Oct;28(11):1628-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of postoperative multiple hepatic metastasis from esophageal cancer successfully treated by surgical resection and hepatic arterial infusion chemotherapy].
  • A 66-year-old male who underwent radical resection for esophageal cancer (stage IV) was diagnosed with multiple hepatic metastasis 1 year and 3 months after the surgery.
  • He underwent hepatic resection and received systemic chemotherapy (FAP: 5-FU, ADR, CDDP), as the post-operative adjuvant therapy.
  • One year and 3 months later, there was a huge recurrence in the residual liver and hepatic arterial infusion chemotherapy (FAP) was performed.
  • The recurrent lesion disappeared completely after 3 sessions of arterial infusion chemotherapy.
  • The arterial infusion chemotherapy was continued in the outpatient clinic and the recurrent lesion is well controlled.
  • The utility of hepatic arterial infusion chemotherapy and hepatectomy for postoperative multiple hepatic metastasis from esophageal cancer was shown in the present case.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / pathology. Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Drug Administration Schedule. Fluorouracil / administration & dosage. Hepatic Artery. Humans. Infusions, Intra-Arterial. Lymphatic Metastasis. Male

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11707996.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; FAP protocol
  •  go-up   go-down


6. Sandler AB, Kindler HL, Einhorn LH, Mitchell E, Masters G, Kraut M, Nicol S, Raghavan D: Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction. Ann Oncol; 2000 Sep;11(9):1161-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction.
  • BACKGROUND: There were approximately 12,500 cases of esophageal carcinoma diagnosed in the US in 1992 and 12,200 deaths.
  • The impact of chemotherapy on patients with metastatic disease is marginal with a median survival of only five months.
  • Gemcitabine has shown interesting clinical activity in initial phase II clinical trials in a variety of malignancies, including the aerodigestive malignancies, squamous-cell carcinoma of the head/neck and both non-small-cell and small-cell lung cancer.
  • PATIENTS AND METHODS: A total of 21 patients with chemotherapy-naïve metastatic esophageal carcinoma were entered.
  • This four-week schedule defined a cycle of treatment.
  • CONCLUSIONS: At the dose and schedule studied it would appear that gemcitabine has no activity in patients with chemotherapy-naïve esophageal carcinoma.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11061612.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


7. Matono S, Fujita H, Sueyoshi S, Tanaka T, Yamana H, Shirouzu K: Long-term survival after three-field lymph-adenectomy for an adenocarcinoma in Barrett's esophagus with metastasis to Virchow's node. Jpn J Thorac Cardiovasc Surg; 2006 Jan;54(1):11-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after three-field lymph-adenectomy for an adenocarcinoma in Barrett's esophagus with metastasis to Virchow's node.
  • Here, we report a case of long-term survival after resection of an adenocarcinoma in Barrett's esophagus with metastasis to Virchow's node.
  • A 71-year-old woman was referred to our hospital with a tumor in the lower third of the thoracic esophagus, located just beneath the tracheal bifurcation because of an hiatal hernia.
  • The esophageal tumor and this lymph node were biopsied.
  • They were pathologically found to be an adenocarcinoma in the esophagus which had metastasised to the lymph node.
  • The pathological diagnosis was adenocarcinoma in Barrett's esophagus with the UICC stage classification of pT1, pN1, pM1-LYM, Stage IVB.
  • She received postoperative chemotherapy of cisplatin combined with 5-fluorouracil.
  • We recommend thoracoabdominal esophagectomy with three-field lymphadenectomy for an advanced carcinoma in the upper and middle thoracic esophagus regardless of histological types.
  • [MeSH-major] Adenocarcinoma / surgery. Barrett Esophagus / complications. Esophageal Neoplasms / surgery. Lymph Node Excision / methods
  • [MeSH-minor] Abdomen. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Esophagectomy. Female. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Mediastinum. Neck. Survivors. Treatment Outcome

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2003 May;27(5):571-9 [12715226.001]
  • [Cites] J Thorac Cardiovasc Surg. 1998 Dec;116(6):954-9 [9832686.001]
  • [Cites] Ann Thorac Cardiovasc Surg. 2002 Dec;8(6):328-35 [12517291.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4592-6 [14673047.001]
  • [Cites] Dig Surg. 2003;20(3):229-35; discussion 236-7 [12759503.001]
  • [Cites] World J Surg. 1994 Mar-Apr;18(2):266-72 [8042333.001]
  • [Cites] World J Surg. 2003 Sep;27(9):1052-7 [12917758.001]
  • [Cites] Surgery. 1995 Nov;118(5):845-55 [7482272.001]
  • [Cites] Ann Surg. 2000 Sep;232(3):353-61 [10973385.001]
  • (PMID = 16482930.001).
  • [ISSN] 1344-4964
  • [Journal-full-title] The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi
  • [ISO-abbreviation] Jpn. J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Nakajima Y, Nagai K, Maruyama M, Kumagai Y, Nara S, Inoue H, Kawano T, Arii S, Iwai T: [Hepatic arterial infusion chemotherapy for liver metastasis from esophageal squamous cell carcinoma]. Gan To Kagaku Ryoho; 2000 Oct;27(12):1911-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatic arterial infusion chemotherapy for liver metastasis from esophageal squamous cell carcinoma].
  • Since 1993, we have treated 9 patients with liver metastases from esophageal squamous cell carcinoma using hepatic arterial infusion chemotherapy (HAI).
  • These patients underwent esophagectomy and reconstruction with a stomach roll, and without preoperative chemotherapy and/or radiotherapy, HAI was effective in 5 patients (56%) with a CR in 2 patients.
  • Preceding systemic chemotherapy was done with 7 patients, and was effective in 3 of them.
  • However, the nausea, vomiting, diarrhea, and/or myelosuppression seen with the preceding systemic chemotherapy were not experienced.
  • In spite of the technical difficulties in catheterization and toxicities to stomach roll, HAI is considered to be more effective and feasible than systemic chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Esophageal Neoplasms / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Drug Administration Schedule. Esophagectomy. Female. Fluorouracil / administration & dosage. Hepatic Artery. Humans. Infusions, Intra-Arterial. Male. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11086444.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


9. Nakajima Y, Nagai K, Kawano T, Inoue H, Nara S, Kumagai Y, Iwai T: Therapeutic strategy for postoperative liver metastasis from esophageal squamous cell carcinoma; clinical efficacy of and problem with hepatic arterial infusion chemotherapy. Hepatogastroenterology; 2001 Nov-Dec;48(42):1652-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic strategy for postoperative liver metastasis from esophageal squamous cell carcinoma; clinical efficacy of and problem with hepatic arterial infusion chemotherapy.
  • BACKGROUND/AIMS: Despite recent advances in diagnosis and treatment, the prognosis for esophageal squamous cell carcinoma is unsatisfactory.
  • Liver recurrence is frequent in postoperative esophageal squamous cell carcinoma patients, and the prognosis for patients with liver metastasis is poor.
  • This report concerns the therapeutic strategy, especially the efficacy of and the problem with hepatic arterial infusion chemotherapy for liver metastasis from esophageal squamous cell carcinoma.
  • All patients underwent esophagectomy and reconstruction with stomach roll without preoperative chemotherapy and/or radiotherapy.
  • For 6 patients, preceding systemic chemotherapy was performed before hepatic arterial infusion.
  • Hepatic arterial infusion was effective for responders to preceding systemic chemotherapy, but ineffective for non-responders.
  • Two patients developed stomach roll ulcers and one experienced the catheter thrombosis, but there were no instances of severe toxicity or complications.
  • CONCLUSIONS: For postoperative liver recurrence of esophageal squamous cell carcinoma, hepatic arterial infusion is the favorable therapy in terms of efficacy and low-grade toxicity, but has a risk of causing severe complications.
  • We consider it suitable that when preceding systemic chemotherapy is performed before hepatic arterial infusion, hepatic arterial infusion is performed in responders to preceding systemic chemotherapy, and that hepatic arterial infusion is continued as long as possible.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Esophageal Neoplasms / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Aged. Female. Hepatic Artery. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11813593.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


10. Akita H, Doki Y, Yano M, Miyata H, Miyashiro I, Ohigashi H, Ishikawa O, Nishiyama A, Imaoka S: Effects of neoadjuvant chemotherapy on primary tumor and lymph node metastasis in esophageal squamous cell carcinoma: additive association with prognosis. Dis Esophagus; 2009;22(4):291-7
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of neoadjuvant chemotherapy on primary tumor and lymph node metastasis in esophageal squamous cell carcinoma: additive association with prognosis.
  • Neoadjuvant chemotherapy (NACT) is widely used to treat esophageal squamous cell carcinoma with lymph node metastasis (ESCC).
  • However, NACT frequently has differential effects on primary tumor (PT) and lymph node metastasis (LNM).
  • Reduction in tumor size of PT and LNM was evaluated separately in 47 node-positive ESCC patients undergoing NACT, followed by surgical resection.
  • Multivariate analysis identified neither the PT nor the LNM response alone as an independent prognostic factor; however the combined PT/LNM response was identified as an independent prognostic factor (hazard ratio [HR] 2.861, P = 0.0255) in addition to the number of histological lymph node metastases (HR 2.551, P = 0.0328).

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19021686.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Makino T, Doki Y, Miyata H, Yasuda T, Yamasaki M, Fujiwara Y, Takiguchi S, Higuchi I, Hatazawa J, Monden M: Use of (18)F-fluorodeoxyglucose-positron emission tomography to evaluate responses to neo-adjuvant chemotherapy for primary tumor and lymph node metastasis in esophageal squamous cell carcinoma. Surgery; 2008 Nov;144(5):793-802
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of (18)F-fluorodeoxyglucose-positron emission tomography to evaluate responses to neo-adjuvant chemotherapy for primary tumor and lymph node metastasis in esophageal squamous cell carcinoma.
  • BACKGROUND: Neoadjuvant chemotherapy (NACT) targets lymph node metastasis (LN), as well as the primary tumor (PT) in esophageal squamous cell carcinomas (ESCC). (18)F-fluorodeoxyglucose-positron emission tomography (FDG-PET) reflects viable tumor volume and may be more useful for evaluating NACT responses than conventional radiography.
  • The NACT response was evaluated separately by both PET and computed tomography (CT) for each PT and LN.
  • The NACT response should be evaluated for both LN and PT because of their different behaviors during chemotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / radionuclide imaging. Esophageal Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Cohort Studies. Disease-Free Survival. Esophagectomy. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Predictive Value of Tests. Retrospective Studies. Tumor Burden

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19081023.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


12. Shuto K, Ohira G, Kono T, Natsume T, Tohma T, Sato A, Ota T, Saito H, Akutsu Y, Uesato M, Matsubara H, Okazumi S, Kaiho T: [Regional treatment of esophageal liver metastasis by intra-arterial low-dose 5-FU therapy]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2409-11
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Regional treatment of esophageal liver metastasis by intra-arterial low-dose 5-FU therapy].
  • The prognosis of esophageal liver metastasis remains poor because of the high incidence of synchronous metastasis in other area and insufficient response to systemic chemotherapy.
  • We assessed loco-regional anticancer potential of intra-arterial 5-FU chemotherapy for esophageal liver metastasis aimed at combination with systemic chemotherapy, radiotherapy and ablation therapy as a multidisciplinary treatment.
  • Six patients of esophageal cancer with liver metastasis and without extra-hepatic metastasis were enrolled.
  • Intra-aortic chemotherapy consisted of 5-FU (250 mg/body) in a one-shot infusion or a continuous infusion for 7 days with 2-week intervals until failure.
  • The responses of liver metastasis were 2 cases of CR, 3 of PR and 1 of SD.
  • The maximum time to progression was 53 months.
  • Two cases had catheter failure and the treatment was interrupted.
  • Liver metastases were controlled well until death in all cases except one.
  • Low-dose intra-aortic 5-FU chemotherapy provided a good regional response and a combination with systemic chemotherapy may prolong survival for the patients of liver metastasis of esophageal cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Esophageal Neoplasms / pathology. Fluorouracil / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224589.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Takemura M, Osugi H, Lee S, Kaneko M, Tanaka Y, Fujiwara Y, Nishizawa S, Iwasaki H, Higashino M: [A resected case of thoracic esophageal cancer in which pCR was obtained using low-dose of nedaplatin (CDGP)/5-FU and radiotherapy]. Gan To Kagaku Ryoho; 2004 Sep;31(9):1399-402
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A resected case of thoracic esophageal cancer in which pCR was obtained using low-dose of nedaplatin (CDGP)/5-FU and radiotherapy].
  • This is a report of a case with esophageal cancer in which pathological CR was obtained by neoadjvant chemoradiotherapy using a low-dose of nedaplatin (CDGP)/5-FU.
  • A protuberant lesion diagnosed as esophageal cancer was found in the middle thoracic esophagus by esophagography.
  • Since another lesion in the upper thoracic esophagus was revealed by endoscopy, metastasis to the cervical lymph nodes was diagnosed by ultrasonography, and preoperative chemoradiotherapy combining a low dose of CDGP/5-FU with radiotherapy was performed.
  • As side effects of this treatment, grade 2 stomatitis and granulocytopenia were observed.
  • The main lesion of the esophagus was found to have significantly diminished through endoscopy after completion of the treatment, and with no malignant cells obtained by biopsy.
  • It was diagnosed as partial response (PR) through imaging diagnosis.
  • Radical resection of esophageal cancer under right thoracotomy and laparotomy was performed.
  • Pathological examination of resected specimens revealed no viable cancer cells in the esophagus or metastasis to the dissected lymph nodes.
  • Neoadjuvant chemoradiotherapy using a low-dose of CDGP/5-FU is an effective treatment for esophageal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Esophagectomy. Fluorouracil / administration & dosage. Humans. Male. Organoplatinum Compounds / administration & dosage. Remission Induction

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15446565.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Saito H, Shuto K, Ota T, Toma T, Ohira G, Natsume T, Uesato M, Akutsu Y, Kono T, Matsubara H: [A case of long-term survival after resection for postoperative solitary adrenal metastasis from esophageal adenocarcinoma]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2406-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of long-term survival after resection for postoperative solitary adrenal metastasis from esophageal adenocarcinoma].
  • He was diagnosed to have an advanced esophageal adenocarcinoma in the middle thoracic esophagus for which chemoradiation therapy was started.
  • He received a course of systemic chemotherapy so called FP therapy and five months later, a course of combination chemotherapy with 700 mg/m2 5-FU on days 1-5 and 70 mg/m2 nedaplatin on day 1 was administered.
  • Since no metastases could be identified in other sites, right adrenalectomy was performed.
  • Surgical resection may contribute to improving the prognosis of solitary adrenal metastasis of esophageal cancer without the other noncurative factors.
  • [MeSH-major] Adenocarcinoma / pathology. Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / surgery. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery
  • [MeSH-minor] Adrenalectomy. Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoembryonic Antigen / blood. Esophagectomy. Fluorodeoxyglucose F18. Fluorouracil / administration & dosage. Humans. Lymph Node Excision. Male. Organoplatinum Compounds / administration & dosage. Positron-Emission Tomography

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224588.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Carcinoembryonic Antigen; 0 / Organoplatinum Compounds; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


15. Sanyal S, Kaman L, Sinha SK: Splenic metastasis from esophageal cancer: report of a case. Surg Today; 2005;35(11):988-90
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Splenic metastasis from esophageal cancer: report of a case.
  • The spleen is an unusual site of metastasis from an esophageal malignancy.
  • We herein report the case of a 25-year-old woman who underwent a transhiatal esophagectomy and adjuvant radiotherapy and chemotherapy for squamous cell carcinoma of the lower third of the esophagus with pN1 lymph node metastasis.
  • Fifteen months following surgery she was found to have splenic metastasis infiltrating the tail of the pancreas at the hilum.
  • A splenectomy, distal pancreatectomy, and resection of the splenic flexure with colocolic anastomosis were performed.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Esophageal Neoplasms / pathology. Splenic Neoplasms / secondary

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 1963 Jul;40:58-66 [13933237.001]
  • [Cites] World J Surg. 1985 Jun;9(3):468-76 [4040300.001]
  • [Cites] Surg Today. 1994;24(5):410-4 [8054811.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1336-7 [14571731.001]
  • [Cites] Cancer. 1987 Jul 1;60(1):100-2 [3581023.001]
  • [Cites] Arch Pathol Lab Med. 2000 Apr;124(4):526-30 [10747308.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Dec;22(6):1011-3 [12467831.001]
  • (PMID = 16249859.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


16. Nettesheim O, Höffken G, Gahr M, Breidert M: [Haematemesis and dysphagia in a 20-year-old woman with congenital spine malformation and situs inversus partialis]. Z Gastroenterol; 2003 Apr;41(4):319-24
Hazardous Substances Data Bank. PHENOXYBENZAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Haematemesis and dysphagia in a 20-year-old woman with congenital spine malformation and situs inversus partialis].
  • [Transliterated title] Hämatemesis und Dysphagie bei 20 Jahre alter Frau mit kongenitalem kaudalen Regressionssyndrom und Situs inversus partialis.
  • A 20-year-old woman with a four-week history of dysphagia, weight loss of four kilograms and unspecific abdominal pain was admitted because of sudden haematemesis.
  • The physical examination showed a patient with a prominent kyphoskoliosis.
  • Upper endoscopy demonstrated a 4 cm large, exophytically growing necrotic tumour of the oesophagus.
  • The CT scan showed a space occupying tumour of the oesophagus and metastases in a size of 1.5 cm in both lungs.
  • Staging after the 6 th dose cisplatin (100 mg/m2/die) and 5-fluorouracil (5 x 1000 mg/m2/die) showed a mild reduction of the tumour and the metastases.
  • The patient died ten months later of multiorgan failure after severe progress of tumour and metastatic growth.
  • The manifestation of squamous cell carcinoma of the oesophagus is unusual in people at the age of twenty.
  • Genetic and chromosomal analysis of the patient gave no evidence for a hereditary disorder.
  • Drug history revealed that the patient had been treated with the alpha-receptor blocking drug phenoxybenzamine over at least 12 years for bladder dysfunction.
  • By the German admission board phenoxybenzamine is only recommended for short term therapy.
  • It seems to be likely that even in humans phenoxybenzamine acts as a mutagenic substance and should be carefully used in long-term treatment.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Deglutition Disorders / etiology. Esophageal Neoplasms / diagnosis. Hematemesis / etiology. Kyphosis / congenital. Lung Neoplasms / secondary. Neural Tube Defects / diagnosis. Scoliosis / congenital. Situs Inversus / diagnosis. Spina Bifida Occulta / diagnosis
  • [MeSH-minor] Adrenergic alpha-Antagonists / adverse effects. Adrenergic alpha-Antagonists / therapeutic use. Adult. Biopsy. Esophagus / pathology. Female. Humans. Long-Term Care. Neoplasm Staging. Phenoxybenzamine / administration & dosage. Phenoxybenzamine / adverse effects. Urinary Bladder, Neurogenic / congenital. Urinary Bladder, Neurogenic / drug therapy


17. Jacobs TM, Rosen GM: Photodynamic therapy as a treatment for esophageal squamous cell carcinoma in a dog. J Am Anim Hosp Assoc; 2000 May-Jun;36(3):257-61
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy as a treatment for esophageal squamous cell carcinoma in a dog.
  • Intrathoracic esophageal squamous cell carcinoma was diagnosed by endoscopy in an 11-year-old, castrated male Labrador retriever with signs of regurgitation and weight loss.
  • Photodynamic therapy with photofrin was administered three times under endoscopic guidance over a two-month period.
  • A partial response to photodynamic therapy was supported by a reduction in tumor size (noted on serial endoscopic examinations) and by a return to oral alimentation.
  • The dog was euthanized due to recurrent regurgitation and aspiration pneumonia nine months after the onset of therapy.
  • Necropsy revealed marked local invasiveness and regional lymph node metastasis of the esophageal squamous cell carcinoma in addition to pneumonia.
  • The application of photodynamic therapy in the treatment of canine esophageal squamous cell carcinoma is discussed and compared with the human literature.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / veterinary. Dihematoporphyrin Ether / therapeutic use. Dog Diseases / drug therapy. Esophageal Neoplasms / veterinary. Photochemotherapy / veterinary

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10825099.001).
  • [ISSN] 0587-2871
  • [Journal-full-title] Journal of the American Animal Hospital Association
  • [ISO-abbreviation] J Am Anim Hosp Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


18. Fujisaki S, Takashina M, Tomita R, Takayama T, Ohmori K, Tomiyama J, Oyama K: [A case of resection of esophageal cancer infiltrating the left main bronchus following preoperative chemo-radiotherapy and resection of metachronous lung metastasis]. Gan To Kagaku Ryoho; 2007 Nov;34(12):1964-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of resection of esophageal cancer infiltrating the left main bronchus following preoperative chemo-radiotherapy and resection of metachronous lung metastasis].
  • We herein report a case of T4 esophageal carcinoma, which was resected after chemo-radiation therapy.
  • In addition, the metachronous lung metastasis was also resected.
  • A 59-year-old female with esophageal carcinoma, which invaded the left main bronchus, underwent chemo-radiation therapy (the combination of systemic chemotherapy of 5-FU/CDDP and external radiation therapy) from January 2004.
  • After the therapy, although the imaging showed a downstaging of esophageal carcinoma, a severe esophageal stricture appeared with ingestion defective.
  • Nine months after esophagectomy, chest CT scan revealed that a solitary pulmonary tumor appeared in S6 of the right.
  • The solitary tumor enlarged gradually.
  • On August 2005, a surgical resection for the solitary pulmonary tumor was performed.
  • Histopathologically, the lesion was compatible for metastasis from esophageal carcinoma.
  • [MeSH-major] Bronchi / surgery. Esophageal Neoplasms / surgery. Lung Neoplasms / secondary. Lung Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219866.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Shiraishi K, Wakita A, Ishigami I, Tomita K, Yamamoto A, Nakayama T, Inaba H, Nishiumi T, Mori T, Isobe K: [Palliative home care of a breast cancer patient with esophageal metastasis after the operation of gastric fistula and tracheotomy--a case study]. Gan To Kagaku Ryoho; 2005 Dec;32 Suppl 1:65-7
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Palliative home care of a breast cancer patient with esophageal metastasis after the operation of gastric fistula and tracheotomy--a case study].
  • A 66-year-old woman felt dysphagia gradually seven years after an operation of breast cancer.
  • We diagnosed her with esophageal metastasis of the breast cancer, and carried out irradiation and outpatient chemotherapy.
  • Because her general condition became worse after the treatment for about four years, we performed an operation of gastric fistula and tracheotomy to manage her nutrition and of an accidental swallowing.
  • Although the patient and her family resisted a discharge from hospital due to the progressive nature of her illness and change in physical surroundings, she was eventually switched to take a homecare medical treatment with the support of a team care approach.
  • The main purposes of the homecare treatment were to manage gastric fistula including the administration of anti-cancer drugs, cervicobrachial pain control and tracheal cannula exchange.
  • Though she was mentally stable and got along well with the family during the home stay, she was hospitalized again two months after the homecare treatment because of aggravated symptoms and the family's fatigue.
  • [MeSH-major] Breast Neoplasms / pathology. Esophageal Neoplasms / secondary. Home Care Services, Hospital-Based. Palliative Care
  • [MeSH-minor] Aged. Esophageal Stenosis / therapy. Female. Gastrostomy. Humans. Patient Care Team. Tracheotomy


20. Takemura M, Osugi H, Lee S, Nishikawa T, Fukuhara K, Iwasaki H: [Pathologic complete response of thoracic esophageal cancer developing after gastrectomy to neoadjuvant low-dose nedaplatin (CDGP), 5-fluorouracil and radiotherapy]. Gan To Kagaku Ryoho; 2005 Jul;32(7):1023-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pathologic complete response of thoracic esophageal cancer developing after gastrectomy to neoadjuvant low-dose nedaplatin (CDGP), 5-fluorouracil and radiotherapy].
  • We treated a 69-year-old man who had developed esophageal cancer following gastrectomy.
  • The cancer located in the middle of the thoracic esophagus, had invaded the trachea and metastasized to cervical lymph nodes according to computed tomography.
  • The esophageal cancer was found by endoscopy to have diminished significantly after completion of neoadjuvant therapy, An endoscopic biopsy specimen was found to contain no malignant cells.
  • The tumor also was smaller by CT, where cervical lymph nodes no longer showed involvement.
  • Partial response was diagnosed based on imaging, and radical resection of the esophageal cancer was performed via right thoracotomy and laparotomy.
  • Pedicled jejunum was used to reconstruct the esophagus through a mediastinal route.
  • Pathologic examination of resected specimens disclosed no viable cancer cells in the esophagus or metastasis to dissected lymph nodes.
  • Neoadjuvant chemoradiotherapy using low-dose CDGP/5-FU is an effective treatment for esophageal cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / radiotherapy. Gastrectomy
  • [MeSH-minor] Aged. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Male. Neoadjuvant Therapy. Organoplatinum Compounds / administration & dosage. Remission Induction

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16044966.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


21. Ikeda Y, Niimi M, Kan S, Shatari T, Takami H, Kodaira S: Conformal radiation therapy for liver metastasis of esophageal carcinoma. Hepatogastroenterology; 2003 Mar-Apr;50(50):532-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conformal radiation therapy for liver metastasis of esophageal carcinoma.
  • Recently, aggressive hepatectomies or hepatic arterial infusion chemotherapy for liver metastasis from gastric or colorectal carcinoma have been performed, and the number of successful studies of liver metastasis have increased.
  • However, there have been few successful cases of liver metastasis from esophageal carcinoma by surgery or chemotherapy.
  • Herein, we show the benefits of radiation therapy for the treatment of liver metastasis from esophageal carcinoma.
  • A 60-year-old woman with a 5-cm solitary liver metastasis from esophageal squamous cell carcinoma was treated with radiation therapy.
  • The daily fraction size was 1.8 Gy, 5 days per week, for a total dose of 54 Gy.
  • During the course of treatment, the patient did not experience any complications.
  • After radiotherapy, abdominal computed tomography showed that the enhanced solid tumor had changed to a very low-density mass lesion with a clear margin, and the size was decreasing gradually between the 6 months.
  • Radiotherapy could be a treatment of choice in patients with liver metastasis from esophageal squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / secondary. Esophageal Neoplasms / pathology. Liver Neoplasms / radiotherapy. Liver Neoplasms / secondary. Radiotherapy, Conformal
  • [MeSH-minor] Female. Humans. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12749266.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


22. Erman M, Karaoğlu A, Oksüzoğlu B, Aydingöz U, Ayhan A, Güler N: Solitary esophageal metastasis of breast cancer after 11 years: a case report. Med Oncol; 2002;19(3):171-5
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary esophageal metastasis of breast cancer after 11 years: a case report.
  • A patient with dysphagia and a history of breast cancer 11 yr ago was admitted to the hospital.
  • A tumor presumably originating from the esophagus was detected.
  • The patient received radiotherapy and chemotherapy consisting of etoposide, adriamycin, and cisplatin.
  • An unexpectedly good response was achieved and the possibility of metastatic breast cancer was reinvestigated.
  • Tamoxifen treatment was started.
  • Solitary esophageal metastasis of breast cancer is a rare event, especially after a remission period lasting more than a decade.
  • Dysphagia in breast cancer patients should raise the suspicion of metastatic disease as well as esophageal cancer and benign strictures.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Esophageal Neoplasms / secondary. Tamoxifen / therapeutic use
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Deglutition Disorders / etiology. Diagnosis, Differential. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Etoposide / administration & dosage. Etoposide / therapeutic use. Female. Humans. Immunohistochemistry. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging. Middle Aged. Radiography. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Clin Oncol. 1997 Dec;27(6):410-4 [9438004.001]
  • [Cites] Gastrointest Endosc. 1988 Jul-Aug;34(4):321-3 [3410243.001]
  • [Cites] J Surg Oncol. 1986 Apr;31(4):240-2 [3724179.001]
  • [Cites] Gastrointest Endosc. 1992 Mar-Apr;38(2):136-41 [1568609.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1085-8 [3300948.001]
  • [Cites] Cancer. 1987 Jul 1;60(1):96-9 [2438031.001]
  • [Cites] Am J Dig Dis. 1970 Jan;15(1):31-6 [5308324.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):2197-201 [9951894.001]
  • [Cites] Dis Chest. 1969 Nov;56(5):449-51 [5347254.001]
  • [Cites] J Natl Cancer Inst. 1971 Jan;46(1):161-70 [5546189.001]
  • [Cites] Gastroenterol Clin North Am. 1991 Dec;20(4):775-89 [1787013.001]
  • [Cites] J Surg Oncol. 1989 Aug;41(4):278-81 [2547117.001]
  • [Cites] Ann Thorac Surg. 1989 Aug;48(2):287-8 [2669651.001]
  • [Cites] Clin Imaging. 1998 Sep-Oct;22(5):343-5 [9755397.001]
  • [Cites] Gastrointest Endosc. 1992 Mar-Apr;38(2):130-5 [1568608.001]
  • [Cites] Acta Cytol. 1996 Jul-Aug;40(4):637-41 [8693878.001]
  • [Cites] Pathol Int. 1997 Sep;47(9):614-7 [9311012.001]
  • [Cites] N Y State J Med. 1976 Jun;76(6):963-5 [180463.001]
  • [Cites] Am J Gastroenterol. 1992 Oct;87(10):1418-23 [1415098.001]
  • (PMID = 12482128.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 094ZI81Y45 / Tamoxifen; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


23. Hashimoto N, Iwazawa J, Abe H, Mitani T, Kagawa K: Radiation therapy for gastric wall metastasis from esophageal carcinoma. Jpn J Radiol; 2010 Apr;28(3):227-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy for gastric wall metastasis from esophageal carcinoma.
  • An 86-year-old man with dysphagia underwent gastrointestinal fiberscopy (GIF) and was found to have a circumferential type 3 advanced carcinoma in the upper thoracic esophagus and a type 2 tumor in the posterior wall of the gastric body.
  • He was diagnosed as having stage IVb (T3N0M1b) esophageal carcinoma with gastric wall metastasis.
  • A total of 60 Gy in 30 fractions of three-dimensional conformal radiation therapy (3D-CRT) was first administered to the esophageal carcinoma, next to the gastric wall metastasis.
  • Concurrent chemotherapy was not given because of the patient's refusal.
  • No subjective morbidity was observed during the treatment.
  • In the GIF study immediately after 3D-CRT, both esophageal and gastric wall tumors had attained a complete response.
  • The dysphagia dissolved as the esophageal tumor shrunk.
  • No local recurrence was observed in either the esophagus or the stomach during follow-up GIF.
  • Considering the dismal prognosis of esophageal carcinoma patients with intramural metastasis to the stomach, a watchful follow-up is needed.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / secondary. Esophageal Neoplasms / pathology. Stomach Neoplasms / radiotherapy. Stomach Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1213-36 [7713784.001]
  • [Cites] Br J Surg. 1948 Jul;36(141):70-3 [18880336.001]
  • [Cites] Cancer. 1985 Nov 1;56(9):2235-41 [4052968.001]
  • [Cites] J Thorac Cardiovasc Surg. 1968 Mar;55(3):396-404 [5644217.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1237-44 [15718321.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1093-103 [10725618.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2774-80 [15254045.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] Acta Radiol Oncol Radiat Phys Biol. 1979;18(2):103-12 [495189.001]
  • [Cites] Cancer. 1981 Jul 15;48(2):329-35 [6453643.001]
  • [Cites] Int J Cancer. 1992 Jan 2;50(1):49-52 [1728612.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3953-8 [16921048.001]
  • [Cites] Cancer. 1982 Oct 15;50(8):1587-90 [7116290.001]
  • (PMID = 20437135.001).
  • [ISSN] 1867-108X
  • [Journal-full-title] Japanese journal of radiology
  • [ISO-abbreviation] Jpn J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


24. Uchikado Y, Natsugoe S, Okumura H, Matsumoto M, Setoyama T, Takigawa J, Haraguchi Y, Ishigami S, Aikou T: [A case of successful treatment by low-dose 5-fluorouracil and cisplatin for liver metastases of esophageal adenosquamous carcinoma]. Gan To Kagaku Ryoho; 2006 Jan;33(1):83-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of successful treatment by low-dose 5-fluorouracil and cisplatin for liver metastases of esophageal adenosquamous carcinoma].
  • Adenosquamous carcinoma of the esophagus is an uncommon type of esophageal tumor.
  • In the present case, a 54-year-old man without symptoms was diagnosed with esophageal squamous cell carcinoma, based on endoscopic examination of a biopsy specimen.
  • Endoscopy and barium roentgenography revealed a superficial plateau-type lesion, 2 cm in length, in the lower esophagus.
  • The histological diagnosis was adenosquamous carcinoma with no lymph node metastasis.
  • Three years after the surgery, multiple liver metastases were detected by computed tomography.
  • The patient was treated with a combination of low-dose 5-fluorouracil(350 mg/body/day) and low-dose cisplatin (7 mg/body/day).
  • Because the first course of chemotherapy was very effective and the number of liver metastases was reduced,a further 6 courses were administered.
  • After 6 courses of chemotherapy, no liver metastases were detected.
  • Based on the present findings, we recommend low-dose 5-fluorouracil/cisplatin therapy for liver metastasis from esophageal adenosquamous carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / secondary. Esophageal Neoplasms / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Cisplatin / administration & dosage. Dose-Response Relationship, Drug. Drug Administration Schedule. Esophagectomy. Fluorouracil / administration & dosage. Humans. Lymph Node Excision. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16410703.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


25. Nakamura T, Matsunami K, Hayashi K, Ota M, Ide H, Takasaki K: Detection of bone marrow micrometastasis in esophageal cancer patients by immunomagnetic separation. Oncol Rep; 2004 May;11(5):999-1003
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of bone marrow micrometastasis in esophageal cancer patients by immunomagnetic separation.
  • Detection of micrometastasis to the bone marrow can predict widespread disease and a poor prognosis of cancer patients.
  • The purpose of this study was to evaluate the clinical significance of detecting micrometastasis in the bone marrow of esophageal cancer patients.
  • Bone marrow and peripheral blood samples were obtained from 52 squamous esophageal cancer patients at the time of surgery.
  • Cytokeratin-positive cancer cells were observed in the bone marrow of 13 (25%) out of 52 patients.
  • Among them, three patients also had cancer cells in the peripheral blood.
  • The presence of bone marrow micrometastasis was correlated with lymph node metastasis (pN) but not associated with depth of tumors (pT).
  • Detection of bone marrow micrometastasis was significantly correlated with VEGF expression of the primary tumors.
  • Detection of cancer cells in the bone marrow might be an indicator of early hematogenous metastasis in esophageal cancer patients.
  • Intensive postoperative chemotherapy seems to be indicated for these patients.
  • [MeSH-major] Bone Marrow Neoplasms / secondary. Esophageal Neoplasms / pathology. Immunomagnetic Separation / methods
  • [MeSH-minor] Aged. Antigens, Neoplasm / metabolism. Female. Humans. Keratin-19. Keratins / metabolism. Male. Middle Aged. Serpins / metabolism. Survival Analysis

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15069538.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Keratin-19; 0 / Serpins; 0 / antigen CYFRA21.1; 0 / squamous cell carcinoma-related antigen; 68238-35-7 / Keratins
  •  go-up   go-down


26. Chen F, Sato K, Sakai H, Miyahara R, Bando T, Okubo K, Hirata T, Date H: Pulmonary resection for metastasis from esophageal carcinoma. Interact Cardiovasc Thorac Surg; 2008 Oct;7(5):809-12
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary resection for metastasis from esophageal carcinoma.
  • Pulmonary metastasectomy has become the standard therapy for various metastatic malignancies to the lungs; however, few data have been available regarding lung metastasectomy for esophageal carcinoma.
  • To confirm a role for resection of pulmonary metastases for such tumors, we reviewed our institutional experience.
  • Between 2001 and 2007, five patients with pulmonary metastases from esophageal carcinoma underwent complete pulmonary resection.
  • All patients had undergone curative resection of their primary esophageal carcinomas and also had obtained locoregional control of their primaries.
  • Disease-free interval varied from 13 to 56 months, with a median of 21 months.
  • In three patients, lung metastases were found to be unilateral and solitary.
  • The other two patients presented several metastases in the unilateral or bilateral lungs.
  • All patients undertook or were going to undertake chemotherapy after the pulmonary metastasectomy.
  • Three patients with solitary metastasis are all alive without disease 13, 48, and 90 months after the first pulmonary metastasectomy, respectively.
  • Pulmonary metastasectomy for esophageal carcinoma with postoperative chemotherapy was seemingly justified.
  • Solitary pulmonary metastasis might be a good candidate for favorable prognostic factor.
  • [MeSH-major] Carcinoma / surgery. Esophageal Neoplasms / pathology. Lung Neoplasms / surgery. Pneumonectomy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Esophagectomy. Female. Humans. Male. Middle Aged. Retrospective Studies. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18556725.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


27. Hedeshian MH, Wang X, Xu B, Fontaine JP, Podbielski FJ: Subcutaneous metastasis from esophageal cancer. Asian Cardiovasc Thorac Ann; 2006 Dec;14(6):520-1
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous metastasis from esophageal cancer.
  • Cutaneous metastases from esophageal adenocarcinoma are exceedingly rare.
  • With the institution of multimodality treatments and surgical resection for esophageal adenocarcinoma, loco-regional disease recurrence has been dramatically reduced.
  • In this report, we present a 59-year-old white male with adenocarcinoma of the distal esophagus that was treated with neoadjuvant chemotherapy and radiation therapy, followed by surgical excision.
  • After a disease free interval of two years the patient presented with cutaneous metastatic disease.
  • [MeSH-major] Adenocarcinoma / secondary. Esophageal Neoplasms / pathology. Skin Neoplasms / secondary
  • [MeSH-minor] Combined Modality Therapy. Fatal Outcome. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17130332.001).
  • [ISSN] 1816-5370
  • [Journal-full-title] Asian cardiovascular & thoracic annals
  • [ISO-abbreviation] Asian Cardiovasc Thorac Ann
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. Ichiki Y, Morita M, Yano K, Sugio K, Yasumoto K, Hirose N: Iris metastasis of esophageal cancer. Ann Thorac Surg; 2005 May;79(5):1782-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Iris metastasis of esophageal cancer.
  • Ocular metastasis in patients with esophageal cancer is quite rare.
  • Several cases have been reported in the literature, but no successful treatments for such metastases have ever been described.
  • We herein report a case of esophageal cancer in which the ocular metastasis was controlled by systemic chemotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Fluorouracil / therapeutic use. Iris Neoplasms / secondary
  • [MeSH-minor] Humans. Male. Middle Aged. Radiotherapy Dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15854985.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] U3P01618RT / Fluorouracil
  •  go-up   go-down


29. Fink W, Zimpfer A, Ugurel S: Mucosal metastases in malignant melanoma. Onkologie; 2003 Jun;26(3):249-51
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosal metastases in malignant melanoma.
  • BACKGROUND: We present the case of a patient with malignant melanoma stage IV according to the American Joint Committee on Cancer (AJCC) classification and an unusual pattern of metastasis to the mucosa of the esophagus, the stomach, the bladder and the palatine tonsil.
  • CASE REPORT: A 38-year-old male patient with metastatic malignant melanoma of stage III (AJCC) was admitted for initiation of adjuvant therapy.
  • 4 months earlier a primary melanoma of the left upper leg had been excised and 2 months later the patient had undergone a left inguinal lymph node dissection revealing 2 metastatic lymph nodes.
  • On admission the patient complained of a sore throat and right cervical lymphadenopathy.
  • He underwent a tonsillectomy and a lymphadenectomy which both revealed melanoma metastases.
  • Two cycles of dacarbazine (DTIC) chemotherapy were performed during which the patient developed cutaneous metastases, dyspepsia, and mild hematemesis.
  • Gastroscopy revealed bleeding from mucosal metastases of the esophagus and stomach.
  • A few weeks later the patient developed macroscopic hematuria.
  • A cystoscopy was performed and showed metastases to the mucosa of the bladder.
  • Nutrient vessels of these bladder metastases were embolized in order to control bleeding.
  • RESULTS: This case presents common and uncommon sites of metastatic melanoma to the mucosa with the typical clinical manifestations in a single patient.
  • [MeSH-major] Esophageal Neoplasms / secondary. Melanoma / secondary. Skin Neoplasms / pathology. Stomach Neoplasms / secondary. Tonsillar Neoplasms / secondary. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Adult. Combined Modality Therapy. Diagnosis, Differential. Gastric Mucosa / pathology. Humans. Male. Mucous Membrane / pathology. Neoplasm Staging. Tomography, Emission-Computed


30. Tokairin Y, Kumagai Y, Yamazaki S: [A case of postoperative liver metastasis of esophageal cancer remains in progression free after successfully resected]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2462-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of postoperative liver metastasis of esophageal cancer remains in progression free after successfully resected].
  • A 59-year-old man admitted for upper gastrointestinal endoscopy of the health examination in the middle of October 2005 was diagnosed with advanced lower esophageal cancer.
  • The histopathological diagnosis was well differentiated squamous cell carcinoma (pT3, ie (+), ly2, v2, pIM0, pN3, pStage III).
  • After two courses of systemic chemotherapy so called FP therapy, solitary liver metastasis in S8 area was detected in May 2007.
  • He received additional two courses of FP chemotherapy, but the CT scan revealed that the lesion was progress disease (PD) in December 2007.
  • It seemed to be difficult to reduce the tumor progression by systemic chemotherapy, so S8 semi-segmental lobectomy was performed.
  • After the operation, the patient received the combination chemotherapy with docetaxel and nedaplatin once a week on day 1 for 4 weeks in five courses, but the CT scan revealed the appearance of the recurrence of residual liver and abdominal lymphnodes in January 2009.
  • The patient also received chemoradiotherapy after the operation, no recurrence of the liver and lymphnodes metastases has been shown.
  • Surgical resection was sometimes seemed to be effective for treating liver metastasis of esophageal cancer, thus indication of operation need to be discussed for accumulation of many liver metastasis of esophageal cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / pathology. Liver Neoplasms / secondary. Liver Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Esophagectomy. Hepatectomy. Humans. Lymph Node Excision. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037456.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down






Advertisement